RT Journal Article
SR Electronic
T1 C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 510
OP 524
DO 10.21873/cgp.20518
VO 22
IS 4
A1 OTANI, YUSUKE
A1 MAEKAWA, MASAKI
A1 TANAKA, ATSUSHI
A1 PEÑA, TIRSO
A1 CHIN, VANESSA D.
A1 ROGACHEVSKAYA, ANNA
A1 TOYOOKA, SHINICHI
A1 ROEHRL, MICHAEL H.
A1 FUJIMURA, ATSUSHI
YR 2025
UL http://cgp.iiarjournals.org/content/22/4/510.abstract
AB Background/Aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.Materials and Methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50’s impact on melanoma progression and patient prognosis.